2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Research, Fundamental Science, Translational Research, Clinical Research, Health Disparities Research, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

4672 P-selectin inhibition improves microvascular hemodynamics and cerebral brain volumes in aging sickle cell mice

Jahnavi Gollamudi, MD, Srivani Gowru, PhD2, Asem Singh, PhD3, Opeyemi Fasina, PhD4, Rowan Goldin5, Emma Musheno, N/A6, Donatien Toukam Kamdem, PhD7, Oluwabukola Gbotosho, PhD8, Hyacinth Hyacinth, MD, PhD, MPH9
1 Division of Hematology, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
2 Department of Neurology and Rehabilitation, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
3 Indigenous Research and Development Institution, Imphal, India
4 Department of Neurology and Rehabilitation, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
5 Rugters New Jersey Medical School, Department of Neurology, Newark, New Jersey, United States
6 University of Cincinnati, Cincinnati, Ohio, United States
7 Department of Internal Medicine/Division of Hematology-Oncology, Cincinnati, United States, University of Cincinnati, Cincinnati, Ohio, United States
8 Department of Neurology and Rehabilitation, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States
9 Department of Neurology and Rehabilitation, Cincinnati, Ohio, United States, University of Cincinnati, Cincinnati, Ohio, United States

Cerebral vasculopathy contributes to cognitive impairment in sickle cell disease (SCD). We previously demonstrated that 13-month-old Townes sickle (SS) mice recapitulate features of SCD-associated cerebral vasculopathy, including vessel tortuosity, more frequent and larger cortical microinfarcts, increased cerebral microvascular P-selectin deposition, and cognitive deficits compared to age-matched control (AA) mice. Based on these findings, we hypothesized that P-selectin plays a central role in the development of cerebral microvasculopathy and its downstream consequences, such as microinfarcts and gray matter loss. In the present study, we evaluated the effects of genetic and pharmacologic p-selectin inhibition on cerebral microvascular hemodynamics, vasculopathy, gray matter volumes, and cortical microinfarcts in SCD.

Male bone marrow chimeric mice expressing P-selectin (B6) or lacking P-selectin (Psel KO) were generated by transplanting AA or SS bone marrow into C57BL/6 or Psel−/− recipients, respectively. In parallel, 6-month-old Townes SS mice received weekly intraperitoneal injections of either an anti-P-selectin (psel) antibody or isotype IgG control up to 6 months. We used a longitudinal cross-section design, and all cohorts were evaluated at 8, 10, and 12 months of age.  All mice underwent in vivo MRI/MRA followed by two-photon (2P) microscopy, after which brains were collected for histological assessment of cortical microinfarct prevalence and size. Cerebral hemodynamic parameters, including mean blood flow velocity, red blood cell (RBC) flux, and leukocyte (WBC) stalls, were quantified from 2P line-scan images using custom MATLAB algorithms, while capillary RBC stalls were identified from z-stack images. Gray matter volumes in 26 cortical and subcortical regions associated with cognitive function were quantified from T2-weighted MRI in Analyze 12 software. Large-vessel tortuosity of the middle cerebral, anterior cerebral, and internal carotid arteries was quantified manually within standardized regions of interest. Small-vessel tortuosity was quantified using custom MATLAB codes based on the DeepVess algorithm. Statistical analyses were performed using either ANOVA or t-tests in GraphPad Prism v11.0.2.

In total, we included 22 B6 AA, 19 B6 SS, 19 PselKO AA, and 20 PselKO SS mice. RBC flux was 4-17 fold higher in 8 and 10 month old PselKO SS mice (n = 5/time point) than in age-matched B6 SS controls (n = 5/time point) (0.08 vs 0.02 nL/s and 0.17 vs 0.01 nL/s, respectively; both p < 0.0001), with no significant difference at 12 months. There were fewer RBC stalls in 8 and 10 month PselKO SS mice compared to B6 SS mice (3.5 vs 1.28 RBC stalls/z-section, 0.87 vs 0.42 RBC stalls/z-section, respectively); however, these were not statistically significant. MRI data at the 12 month timepoint showed PselKO SS mice had 10% larger gray matter volume in regions such as the hippocampus (20.90 vs 19.07 mm3, p < 0.0001) compared to B6 SS mice. Also at 12 months, PselKO SS mice had a significantly lower normalized vessel tortuosity index (less tortuous) than B6 SS mice (0.44 vs 0.46, p < 0.0001). Finally, PselKO SS mice had 2-4 fold fewer microinfarcts compared to B6 SS mice (Number of microinfarcts at 8 months: 30.31 vs 7.46, p = 0.002; 10 months: 40.87 vs 20.41, p = 0.03; 12 months:14.68 vs 6.5, p = 0.09). Also, PselKO SS mice had 2-3 fold smaller microinfarct area compared to B6 SS mice (8 months: 0.34 vs 0.83 mm2, p < 0.001; 10 months: 0.42 vs 0.67 mm2,p=0.013 and 12 months: 0.08 vs 0.23 mm2, p = 0.16). In the antibody-treated mice, 14 SS mice each were injected with isotype control (n=4-5/time point) or anti-Psel antibody (n=4-5/time point). At 10 months, anti-Psel treated mice (n=4), compared to control mice(n=5), had 2-fold higher RBC flux (0.023 vs 0.010 nL/s, p< 0.01), with no significant difference at the 12-month time point. Anti-Psel treatment reduced WBC stalls by 3 fold at 8 months (2.4 vs. 7.2 stalls/100 μm/min;p <0.001) and 2.5 fold at 10 months (4.2 vs. 10.5 stalls/100 μm/min;p <0.001), with no difference at 12 months. Gray matter volumes and tortuosity were not different between treatment and control mice.

In conclusion, P-selectin inhibition in SS mice leads to hemodynamic changes that reduce the severity and burden of microinfarcts and improve downstream vessel remodeling and gray matter volumes in cognition-relevant regions. More research is needed to confirm the potential implications of these results.

Jahnavi Gollamudi, MD: No relevant conflicts of interest to declare.